Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADXS11-001 + pemetrexed
- Development stage
- Unknown
- Lead developer
- Advaxis
- Modality
- Oncolytic Bacteria → Oncolytic Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous (for Pemetrexed), Intravenous Infusion (for ADXS11-001 In Trials)
01
Overview
ADXS11-001 + pemetrexed is an investigational combination therapy consisting of ADXS11-001 (axalimogene filolisbac), a live attenuated Listeria monocytogenes engineered to express a fusion protein (Listeriolysin O and HPV-16 E7) designed to stimulate an immune response against HPV-expressing tumor cells, and pemetrexed, a folate antimetabolite that inhibits several key enzymes involved in folate metabolism and DNA synthesis. The combination is studied as a cancer immunochemotherapy, primarily targeting tumors that are positive for HPV, such as cervical cancer, and may have application in other cancers. ADXS11-001 is developed by Advaxis, while pemetrexed is manufactured by Eli Lilly and other companies[2][5].
- Brand names
- Alimta (for pemetrexed)Pemfexy (for pemetrexed)Pemrydi Rtu (for pemetrexed)Axtle (for pemetrexed)Armisarte (for pemetrexed)Pemetrexed Accord (for pemetrexed)Pemetrexed Fresenius Kabi (for pemetrexed)
- Other names
- ADXS11-001 + pemetrexed
02
Targets
GART (GAR transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on ADXS11-001 + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADXS11-001 + pemetrexed.